A clinical trial of a potential Human Immunodeficiency Virus (HIV) drug farmed from genetically modified (GM) tobacco plants has at long last got underway in the United Kingdom. The beginning of the trial follows several years of regulatory negotiations, and is being carried out by the PHARMA-PLANTA consortium, an international group of 28 academic institutions and 4 small companies. The antiviral preventative P2G12 antibody drug that has been synthesised...
Genetics News
